Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
2h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
MORE than six decades after the last of the peace-loving agrarian families were forcibly uprooted from their banana farms and market gardens by a racist Durban Corporation, Chatsworth is today a ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
In the early 1980s, men and women in the prime of their lives began arriving at Walter Reed Medical Center, wrecked by a disease for which we had no name, ...
To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of USAID funding ...
The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback